SCHEMBL2321346

SCHEMBL2321346

C[Si](C)(C)CCOCn1cnc2cc(Cl)c(I)cc21

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KCNH2 Q12809 1/20 0.34
BRD4 O60885 5/20 0.33
CREBBP Q92793 2/20 0.33
LMNA P02545 5/20 0.33
RAB9A P51151 3/20 0.33
NPC1 O15118 2/20 0.33
PKM P14618 1/20 0.33
GAA P10253 1/20 0.33
DGAT1 O75907 2/20 0.32
EP300 Q09472 1/20 0.32
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PRPS1 P60891 2/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2541707 0.96 MEN1 (0.36) MEN1KMT2AKCNH2BRD4CREBBP
SCHEMBL14502048 0.89 MEN1 (0.38) MEN1KMT2AKCNH2BRD4CREBBP
SCHEMBL5953458 0.83 MEN1 (0.45) MEN1KMT2AKCNH2BRD4LMNA
SCHEMBL5951458 0.80 MEN1 (0.56) MEN1KMT2AKCNH2LMNARAB9A
SCHEMBL31376396 0.79 BRD4 (0.36) MEN1KMT2AKCNH2BRD4CREBBP
SCHEMBL15749768 0.79 BRD4 (0.36) MEN1KMT2AKCNH2BRD4CREBBP
SCHEMBL31450920 0.79 SMN1; SMN2 (0.38) MEN1KMT2ABRD4CREBBPLMNA
SCHEMBL5948882 0.79 OPRL1 (0.39) MEN1KMT2AKCNH2
SCHEMBL14502057 0.79 GGPS1 (0.44) MEN1KMT2AKCNH2BRD4CREBBP
SCHEMBL2318726 0.78 NPC1 (0.33) NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2348857-B1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME (US) 2016-02-24 EP disclosed
US-8410284-B2 Cyclic benzimidazole derivatives useful as anti-diabetic agents MERCK SHARP & DOHME CORP (US) 2013-04-02 US disclosed
US-20110263533-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. 2011-10-27 US disclosed
EP-2348857-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS Merck Sharp & Dohme Corp. (US) 2011-08-03 EP disclosed
WO-2010047982-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263533-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 MEN1 3565/4885KMT2A 2171/4885KCNH2 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.